

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
CATEGORY 1 INNOVATIVE DRUG “TQC2938” INJECTION APPROVED FOR
CLINICAL TRIAL

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Category 1 innovative drug “TQC2938” injection developed by the Group has been approved by the National Medical Products Administration of the People’s Republic of China, to commence clinical trials for the treatment of moderate to severe asthma.

TQC2938 is a humanised IgG2 monoclonal antibody targeting ST2 (interleukin-33 (IL-33) receptor) and belongs to therapeutic biological product Category 1. TQC2938 specifically binds to human ST2, blocking its interaction with IL-33 ligands, blocking signalling pathway of ST2/IL-33, reducing the production of downstream Th2 cytokines (IL-4, IL-5, IL-13, etc.) and reducing the level of eosinophils and other inflammatory cells, thereby reducing the occurrence of asthma and improving patients’ quality of life. Pre-clinical animal efficacy trials have shown that the candidate molecules can significantly improve disease symptoms.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 14 June 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.